| Title |
Phase I Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults |
| Description |
This is a Phase I trial to evaluate the safety and tolerability, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity of a single dose of GB223 in healthy subjects in a randomized, double-blind, placebo-controlled, single-dose escalation design. |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Proteomic Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA015167 |
| Release Date |
2024-12-31 |
| Submitter |
Haiyan Liu (haiyanliu36049@yeah.net) |
| Organization |
The Fifth Affiliated Hospital of Guangzhou Medical University |
| Submission Date |
2023-02-23 |